Patients with R/R FL continue to relapse due to this chronic and incurable disease1,2

Various medicine icons

FL isn’t curable, and patients continue to experience shorter remissions with disease progression

  • After 2 lines of treatment, relapses are still expected2,3
3 patients icon

Most therapies involve complicated dosing schedules and cumulative toxicity1,4

Your patients deserve more options

An established treatment that delivers high response rates and durable outcomes with one infusion in R/R FL

FL, follicular lymphoma; R/R, relapsed or refractory.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.

  1. Cahill KE, Smith SM. Follicular lymphoma: a focus on current and emerging therapies. Oncology. 2022;36(2):97-106. doi:10.46883/2022.25920946
  2. Kanters S, Ball G, Kahl B, et al. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. BMC Cancer. 2023;23(1):74. doi:10.1186/s12885-023-10546-6
  3. Skarbnik AZ, Patel K. Treatment selection for patients with relapsed or refractory follicular lymphoma. Front Oncol. 2023;13:1120358. doi:10.3389/fonc.2023.1120358
  4. Qualls D, Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica. 2022;107(1):19-34. doi:10.3324/haematol.2021.278717